Endothelial cell hyperplasia contributes to thrombosis in heparin- induced thrombocytopenia

Seminars in Thrombosis and Hemostasis

Volumn 25, Issue 2 SUPPL. 1, 1999, Pages 23-27

  Kwaan, Hau C ^a   Sakurai, Shumpei ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Endothelial cell hyperplasia; Heparin; Heparin induced thrombocytopenia; Platelet thrombus; Platelets; Thrombocytopenia

Indexed keywords

GLYCOPROTEIN IB; HEPARIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; THROMBOCYTE FACTOR 4;

ANTICOAGULATION; CELL HYPERPLASIA; CONFERENCE PAPER; ENDOTHELIUM CELL; HEPARINIZATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOGENESIS; THROMBOSIS;

ANTICOAGULANTS; ARTERIES; ENDOTHELIUM, VASCULAR; FACTOR VIII; HEPARIN; HUMANS; HYPERPLASIA; IMMUNOHISTOCHEMISTRY; PLATELET GLYCOPROTEIN GPIB-IX COMPLEX; THROMBOCYTOPENIA; THROMBOSIS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 0032917828     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Warkentin TE, Kelton JG. Heparin-induced thrombocytopenia. Prog Hemostas Thromb 1991;10:1-34
2. Schmitt BP, Adelman B. Heparin-associated thrombocytopenia: A critical review and pooled analysis. Am J Med Sci 1993;305: 208-215
3. King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984;100:535-540
4. Kelton JG, Sheridan D, Santos A, et al. Heparin-induced thrombocytopenia: Laboratory studies. Blood 1988;72:925-930
5. Chong BH, Fawaz I, Chesterman CN, et al. Heparin-induced thrombocytopenia: Mechanism of interaction the heparin-dependent antibody with platelet. Br J Haematol 1989;73: 235-240
6. Adelman B, Sobel M, Fujimura T, et al. Heparin-associated thrombocytopenia: Observations on the mechanism of platelet aggregation. J Lab Clin Med 1989;113:204-210
7. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemostas 1992;68:95-96
8. Kelton JG, Smith JW, Warkentin TE, et al. Immunoglobulin G from patients with heparin-induced thrombocytopenia binds to a complex of heparin and platelet factor 4. Blood 1994;83:3232-3239
9. Greinacher A, Pötzsch B, Amiral J, et al. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen. Thromb Haemostas 1994;71:247-251
10. Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Gin Invest 1994;93:81-88
11. Amiral J, Wolf M, Fischer AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996;92: 954-959
12. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996;88:410-416
13. Warkentin TE, Hayward CPM, Boshkov LK, et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 1994;84:3691-3699
14. Cines DB, Tomaski A, Tannenbaum S. Immune endothelial-cell injury in heparin-associated thrombocytopenia. N Engl J Med 1987;316:581-589
15. Greinacher A, Michels I, Mueller-Eckhardt C. Heparin-associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemostas 1992;67:545-549
16. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-pcroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 1981;29:577-580
17. Weismann RE, Tobin RW. Arterial embolism occurring during systemic heparin therapy. Arch Surg 1958;76:219-227
18. Towne JB, Bernhard VM, Hussey C, et al. White clot syndrome: Peripheral vascular complications of heparin therapy. Arch Surg 1979;114:372-377
19. Benhamou AC, Gruel Y, Barsotti J, et al. The white clot syndrome or heparin associated thrombocytopenia and thrombosis (WCS or HATT) (26 cases). Int Angiol 1985;4:303-310
20. White PW, Sadd JR, Nensel RE. Thrombotic complications of heparin therapy. Including six cases of heparin-induced skin necrosis. Ann Surg 1979;190:595-608
21. MacLean JA, Moscicki R, Bloch KJ. Adverse reactions to heparin. Ann Allergy 1990;65:254-259
22. Leblanc M, Roy LE, Legault L, et al. Severe skin necrosis associated with heparin in hemodialysis. Nephron 1994;68:133-137
23. Christiaens GC, Nieuwenhuis HK. Images in clinical medicine. Heparin-induced skin necrosis. N Engl J Med 1996;335:715
24. Eninger FM, Weiss SW, Soft Tissue Tumors. St. Louis: Mosby, 1983
25. Kwaan HC, Clinicopathologic features of thrombotic thrombocytopenic purpura. Semin Hematol 1987;24:71-81
26. Antoniades HN, Scher CD, Stiles CD. Purification of human platelet-derived growth factor. Proc Natl Acad Sci USA 1979;76:1809-1813
27. Oka Y, Orth DN. Human plasma epidermal growth factor/β-urogastrone is associated with blood platelets. J Clin Invest 1983;72:249-259
28. Miyazono K, Okabe T, Urabe A, et al. Purification and properties of an endothelial cell growth factor from human platelets. J Biol Chem 1987;262:4098-4103
29. a amino acid sequence analysis. Blood 1989;74:1084-1092
30. Karey KP, Sirbasku DA. Human platelet-derived mitogens. II. Subcellular localizalion of insulinlike growth factor I to the α-granule and release in response to thrombin. Blood 1989; 74:1093-1100
31. Assoian RK, Komoriya A, Meyers CA, et al. Transforming growth factor-β in human platelets. J Biol Chem 1983;258: 7155-7160